HZNP - ホライゾン・ファ―マ （Horizon Pharma plc）

Hi everyone,This is a reminder that on February 9, 2023, I will increase the price of the Growth Stock Forum from $299 per year to $399 per year and from $35 per month to $55 per month.If…

Horizon Therapeutics (HZNP) and Amgen (AMGN) confirmed the companies received a "Second Request" from the Federal Trade Commission in regards to the planned almost $28 billion…

Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB ) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-212 for chronic refractory gout. The analyst expects positive top-line data in 1Q23 for SEL-212. While many will likely compare the results to Horizon Therapeutics PLC ''s (NASDAQ: HZNP ) Krystexxa and the various immunomodulating combinations, Canaccord sees SEL-212 as a step ahead in the gout treatment paradigm. The once-a-month treatment sets it apart from Krystexxa. The analyst anticipates a 40-50% … Full story available on Benzinga.com

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) price is hovering lower on Tuesday, January 31, dropping -0.34% below its previous close. A look at today’s price movement shows that the recent level at last check reads $110.05, with intraday deals fluctuating between $110.04 and $110.94. The company’s 5Y monthly beta was ticking 1.18 while its P/E … Where Do Analysts Think The Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) Is Going Read More »

Horizon Therapeutics (HZNP) ticked down 0.3% on a report that Amgen (AMGN) received a so-called 2nd request from the Federal Trade Commission in regards to its planned almost $28…

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial. CAS is a tool designed to evaluate inflammatory signs and symptoms that are often associated with TED.1 Topline results are expected in the second quarter of 2023. TED is a serious,

Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial. CAS is a tool designed to evaluate inflammatory signs and symptoms that are often associated with TED.1 Topline

Tuesday''s top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron Technology, Salesforce, Six Flags Entertainment, Tellurian and Unity Software.

Horizon Therapeutics (HZNP) said it paid a milestone payment to HemoShear Therapeutics for advancing product candidates against a second target to treat gout under their…

Novel Program Supports Student Education and Future Careers in Patient Advocacy Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the Univ…

Horizon Therapeutics (NASDAQ: HZNP) shares jumped 6.5% on March 1, after the biopharmaceutical company delivered stronger-than-expected fourth-quarter results. The post Horizon Therapeutics Delivers Upbeat Results in Q4; Shares Up 6.5% appeared first on Smarter Analyst .

Shares of Horizon Therapeutics (HZNP) are trading higher in the premarket session after its Q4 2021 results beat on the top and bottom lines and it issued 2022 guidance.

Horizon Therapeutics plc''s (NASDAQ: HZNP ) Q4 sales increased 36% Y/Y to $1.014 billion , beating the consensus of $995.87 million. The adjusted gross profit declined slightly from 87.1% to 86.5%, with an adjusted EBITDA of $416.0 million, including $36.2 million of upfront and milestone payments primarily related to the collaboration agreement with Alpine. The Company reported an adjusted EPS of $1.41, up … Full story available on Benzinga.com